NCT03045328View on ClinicalTrials.gov

Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 26, 2017

Primary Completion Date

May 19, 2020

Study Completion Date

August 5, 2021

Conditions
Recurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Small Lymphocytic Lymphoma
Interventions
DRUG

Ibrutinib

Administered at 420 mg/day, as oral capsules (3 x 140 mg), starting Day 1, Week 1.

DRUG

Venetoclax

Administered as tablets, starting Day 1, Week 9, with dose increasing every 7 days through 5 dose levels (20 mg; 50 mg; 100 mg; 200 mg; 400 mg).

Trial Locations (2)

91010

City of Hope, Duarte

94305

Stanford University, School of Medicine, Stanford

All Listed Sponsors
lead

Steven E. Coutre

OTHER

NCT03045328 - Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL | Biotech Hunter | Biotech Hunter